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Abstract.  The E1  glycoprotein of the avian coronavi- 
ms infectious bronchitis  virus contains  a  short, 
glycosylated amino-terminal  domain,  three membrane- 
spanning  domains,  and a  long carboxy-terminal  cyto- 
plasmic  domain.  We show that  E1  expressed from 
cDNA is targeted to the Golgi region,  as it is in in- 
fected cells.  E1  proteins  with precise deletions of the 
first and  second or the second and third membrane- 
spanning  domains  were glycosylated, thus  suggesting 
that  either the first or third  transmembrane  domain 
can function as an internal  signal  sequence.  The mu- 
tant protein with only the first transmembrane  domain 
accumulated intracellulady  like the wild-type protein, 
but the mutant protein with only the third  transmem- 
brane domain was transported  to the cell surface.  This 
result suggests that information  specifying accumula- 
tion in the Golgi region  resides in the first transmem- 
brane domain,  and provides the first example of an in- 
tracellular  membrane protein that  is transported  to the 
plasma membrane after deletion of a  specific domain. 
T 
hE  intracellular  transport  and  targeting  of proteins 
from their site of synthesis to their correct destination 
is a process instrumental  to malntainence of cellular 
integrity. Membrane-bound and secreted proteins are sorted 
from cytoplasmic proteins and those destined for the nucleus 
or mitochrondria  by virtue of a  signal  or leader sequence 
which directs insertion into the lumen of the endoplasmic 
reticulum (Walter et al.,  1984).  Plasma membrane and se- 
creted proteins  follow a  similar pathway through  the cell, 
from the rough  endoplasmic  reticulum  through  the Golgi 
complex en route to the plasma membrane (Sabatini et al., 
1982).  Other proteins in this exocytic pathway are retained 
at points along the way, such as cytochrome P-450 in the en- 
doplasmic  reticulum  (Brands  et al.,  1985)  and  galactosyl 
transferase  in the Golgl complex (Roth and Berger,  1982). 
Lysosomal enzymes are sorted to lysosomes after passage 
through  the Golgi complex.  Some lysosomal enzymes are 
sorted via a specific marker, a mannose-6-phosphate modi- 
fication  of asparagine-linked  (N-linked) 1 oligosaccharides 
of these enzymes, which is recognized by a receptor (Sly and 
Fischer,  1982). 
The process of intracellular transport to the plasma mem- 
brane could be governed by positive sorting signals; i.e. pro- 
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teins with these signals would be transported to the cell sur- 
face  via  a  type  of  receptor-mediated  process,  like  that 
involved in targeting of lysosomal enzymes. Alternatively, as 
recently suggested by Kelly (1985) and Rothman (1986), pro- 
teins that are destined for the plasma membrane or for con- 
stitutive secretion could move passively with the bulk flow 
of lipids,  while proteins secreted in a regulated manner or 
those retained in intracellular membranes would possess sig- 
nals which selectively retain them from moving with the bulk 
flow of membranes. A third model could invoke both positive 
signals that enhance the rate of incorporation of proteins into 
transport vesicles, and negative retention signals that ensure 
intracellular proteins to not be transported beyond a certain 
point. 
Recombinant DNA technology that uses gene expression 
and site-directed mutagenesis offers a powerful approach to 
the study of intracellular transport and targeting.  For exam- 
ple, using this approach, an involvement of cytoplasmic do- 
mains  of proteins  has  been  suggested  in  facilitating  both 
exocytosis  (Rose  and  Bergmann,  1983)  and  endocytosis 
(Lehrman et al.,  1985;  Roth et al.,  1986),  and in targeting 
of proteins to basolateral membranes of polarized epithelial 
cells  (Mostov et al.,  1986;  Puddington  et al.,  1987).  Al- 
though  specific molecules  interacting  with  these domains 
have not yet been identified, these results suggest that impor- 
tant interactions  with cytoplasmic domains do occur. 
Viruses  provide  simple  and  useful  model  systems  for 
studying the signals involved in targeting of membrane pro- 
teins in cells. The coronaviruses provide an especially inter- 
esting model because they bud from intracellular membranes 
rather  than  from the plasma  membrane.  The best-studied 
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(MHV)  and avian infectious  bronchitis  virus  (IBV). Both 
viruses specify two glycoproteins called El and E2 (reviewed 
by Sturman and Holmes, 1985). E2 forms the virion spike 
and can be detected in the plasma membrane as well as intra- 
cellular  membranes of infected  cells.  In contrast,  E1  ac- 
cumulates intracellularly, and thus appears to play a critical 
role in intracellular budding of the virus. The viral nucleo- 
capsid interacts with the MHV E1 protein, presumably the 
cytoplasmic tail, and virion budding occurs at the site of E1 
accumulation in infected cells (Sturman et al., 1980; Dubois- 
Dalque et al.,  1982; Tooze et al.,  1984). 
The sequences of cDNAs encoding E1 proteins from both 
MHV and IBV have been recently reported (Armstrong et 
al., 1984; Boursnell et al.,  1984). These sequences predict 
polypeptides with a similar structure: a short, glycosylated 
amino-terminal  domain,  three  hydrophobic  domains  be- 
lieved to span the membrane three times, and a long cytoplas- 
mic domain at the earboxy terminus. Studies that use pro- 
tease treatment of intact virus (Sturman and Holmes, 1977; 
Cavanagh et al.,  1986) or of E1  inserted into microsomal 
membranes (Rottier et al., 1984) support the model for the 
structure of El. Since there is no cleaved amino-terminal sig- 
nal sequence (Rottier et al., 1984), and the protein is inserted 
into microsomal membranes in a signal recognition parti- 
cle-dependent manner (Rottier et al., 1985), it has been sug- 
gested that one or more of the putative membrane-spanning 
domains functions as an internal, uncleaved signal sequence. 
We report here that the IBV E1 glycoprotein is retained in 
the Golgi region of the cell in the absence of the other viral 
proteins when expressed from cDNA.  In an earlier study 
using gene expression and mutagenesis techniques, we deter- 
mined that the cytoplasmic domain of  the IBV El protein did 
not contain a signal that was capable of retaining the G pro- 
tein of vesicular stomatitis virus (VSV) in intracellular mem- 
branes (Puddington et al., 1986). Thus, in the present study 
we  chose to  search  for a  retention signal  in the amino- 
terminal half of the IBV E1 protein. We report that the first 
of the three membrane-spanning domains may constitute 
such a signal, and our results are discussed in terms of cur- 
rent models for protein transport to the plasma membrane. 
Materials and Methods 
Construction of  an Expression Vector 
Encoding IBV  El 
A cDNA clone encoding the E1 protein of the Beaudette  strain (M42) of 
1BV was derived from viral genomic RNA and kindly provided by D. Stern 
(pIBV-5; Stern, 1983). A subclone containing the entire coding region was 
prepared (p57-6), and the nucleotide sequence was determined by the proce- 
dure of Maxam and Gilbert (1977). This sequence predicts  a polypeptide 
with 225 amino acids, and differs at only two nucleotides from the sequence 
published  by Boursnell et al. (1984) for the El protein of the Beaudette strain 
of IBV. These differences were a T instead of a C at nucleotide  167 and a 
C instead of a T at nucleotide 375, changing the codon for Pro 2 and for 
Thr 71 to that for Ser and Ile, respectively. A fragment that contains the en- 
tire coding sequence of IBV El (773 bp) was excised from p57-6 with Hpa 
I and Hha I, and incubated with the Klenow fragment of DNA polymerase 
I and deoxynucleoside  triphosphates to remove the 3' overhang. After liga- 
tion with Xho I linkers, the fragment was cloned into the unique Xho I site 
of the SV40-based expression vector, pJCll9 (Sprague et al.,  1983), and a 
clone with the insert in the proper orientation for expression from the late 
SV40 promoter was selected (pSV/IBVEI).  This construct includes a 5' un- 
translated region  of 52  nucleotides,  and a  3' untranslated region of 45 
nucleotides. 
Oligonucleotide-directed  Mutagenesis 
Synthetic oligonucleotides  were used to precisely delete coding sequences 
for putative membrane-spanning domains of El. The negative strand of the 
IBV E1 gene was cloned into the Barn HI site of MI3 mp8 as described (Bose 
et al.,  1984), and single-stranded phage DNA was purified  for use as the 
template for mutagenesis.  Synthetic oligonucleotides  (33 mers) were de- 
signed to loop out specific regions of the coding sequence by hybridizing 
with 16 nucleotides  on the 5' side of the loop and 17 nucleotides  on the 3' 
side. The domain junctions were assigned on the basis of secondary  struc- 
ture and hydrophobicity predictions for IBV El (Boursnell et al., 1984; Rot- 
tier et al., 1986). The oligonucleotide  used to generate the coding sequence 
for the mutant protein that lacked the second and third hydrophobic domains 
(Am2,3) was 
5~  GTA~ATC~AACAAGACIL'TI~AAGC  ~- 3' 
and that for the mutant protein that lacked the first and second hydrophobic 
domains (Am1,2) was 
5-'ICAGCI"TTTTAAAGAGGGAGGICr'IGI'C GCAGC  -3'. 
They were synthesized  and purified as p~viously described (Rose et al., 
1984; Machamer et al.,  1985). After hybridization of the oligonucleotide 
with the template DNA, primer extension was carried out with the Klenow 
fragment of DNA polymerase I (Boehringer  Mannheim  Biochemicals, Indi- 
anapolis,  IN) by the procedure previously  described (Adams  and Rose, 
1985; Machamer et al., 1985). After transfection of competent Escherichia 
coil JM103 with the primer extension mixture, plaques containing the muta- 
tions were identified by differential hybridization with the 5'-[32p]-labeled 
oligonucleotide.  DNA containing the mutation was excised and subeloned 
into the expression vector pJC119, and the mutation confirmed by DNA se- 
quence analysis (Maxam and Gilbert, 1977). The mutant protein Am2,3 was 
created by fusion of the codon for Thr 42 to that for Arg 102 (deleting 156 
nucleotides), and Am1,2 by fusion of the codon for Glu 20 to that for Gly 
77 (deleting  168 nucleotides). 
Cells and Virus 
Both COS-1 and HeLa cells were maintained in Dulbecco-Vogt's modified 
Eagle's  medium with 5%  FCS.  The IBV used in these experiments was 
adapted to growth in monkey  cells by nine consecutive  passages  of egg- 
grown virus at low multiplicity of infection in Vero cells, and was obtained 
from B. Sefton (The Salk Institute). Tissue culture supernatant from infected 
Vero cells was used as the inoculum to infect COS-I cells for radiolabeling 
and inununofluorescence.  The multiplicity  of infection was approximately 
0.1, and infected cells were assayed for IBV-speciflc polypeptides  at 29 and 
48 h postinfection. 
Preparation of  Recombinant Vaccinia 
Viruses Encoding El and A ml,2 
DNA encoding wild-type E1 or the mutant protein Aml,2 was excised from 
the SV40 expression vector with Xho I, and the ends were filled in with the 
Klenow fragment of DNA polymerase I. The inserts were then subcloned 
into the vector pSCll (Chakrahatti et al.,  1985) at the unique Sma I site. 
After selection of clones with inserts in the correct orientation for expres- 
sion from the vaccinia promoter PT.SK, supercoiled  DNA was transfected 
onto HeLa cells by calcium phosphate coprecipitation.  The HeLa cells had 
previously been infected at a multiplicity of 0.05 with wild-ty~ vaccinia vi- 
rus 1 h before addition of the DNA. The medium was replaced 18 h later, 
and incubation continued another 2 d. Recombinant virus was isolated by 
including  X-gal (5-bromo-4-chloro-3-indolyl-~-D-~alactolrynmoside; Boeh- 
ringer  Mannheim Biochemicals)  in  the  plaquing overlay  as  described 
(Chakrabarti et al., 1985). The pSCll vector contains the E. coli lacz gene 
under control of a  late vaccinia promoter; thus [5-galactosidase activity 
results in formation of blue plaques by recombinant virus. Recombinant 
viruses encoding E1 or Aml,2 proteins (VVE1 and WArn1,2) were plaque- 
purified  three times in HeLa cells,  and large stocks were prepared. HeLa 
cells (5  x  105) in 35-ram dishes were infected with the recombinant vac- 
cinia viruses at a multiplicity of approximately 4, and analyzed for expres- 
sion 5 h later. 
Antibody Preparation 
A polyclonal rabbit antiserum was raised to a synthetic peptide correspond- 
ing to the carboxy-termina122  amino acids oflBV El. The peptide was con- 
jugated to BSA via the penultimate tyrosiue residue with bis-diazobenzidlne 
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with 1 mg conjugate each, emulsified with 0.75 ml complete Freund's adju- 
vant in a total volume of 1.5 ml. About 30 sites were injected intradermaily 
with 50 ltl per site. Rabbits were boosted with ,~,0.5 mg conjugate (0.75 ml 
total) in the same way every 4 wk.  ELISA titers to the peptide were mea- 
sured in a solid-phase assay that uses a second antibody conjugated  with 
horseradish peroxidase,  and were approximately  1:10,000 after the second 
boost. This titer did not change significantly after repeated boosts. After the 
second boost, the synthetic peptide was discovered  to be incorrect in that 
it contained an extra glycine (after the glycine at position 8 of the peptide), 
and subsequent boosts were performed with the correct synthetic peptide. 
Ability of the antiserum to immunoprecipitate the hybrid protein (323 (Pnd- 
dington et ai., 1986) was detected after the third boost. This titer increased 
until the fifth boost, when one of the two rabbits was producing antibody 
with a  slightly  higher titer than the other with less background in im- 
munoprecipitates.  This antiserum was used for all subsequent experiments. 
Anti-peptide  antibodies  were  affinity  purified  on  Affigel-histamine 
columns coupled with the peptide.  Histamine was coupled to Affi-gel  10 
(Bio-Rad  Laboratories,  Richmond, CA);  the peptide  was then coupled  to 
the conjugated resin via the tyrosine residue with bis-diazobenzidine as de- 
scribed above. 10 mg of peptide was coupled to 1 mi of resin, and remaining 
active groups were blocked with 1 mg/ml ovalbumin. Serum (4 mi) contain- 
ing antibodies to the peptide was incubated with 1 ml of conjugated  resin 
for 4 h at 4~  with end-over-end inversion. After transfer to a column, resin 
was first washed with 20 mi of 10 mM Tris, pH 8.0, with 0.2% deoxycbolate, 
and then with 15 mi of 10 rnM Tris, pH 8.0, containing 0.5 M NaCI. Specific 
antibodies were eluted with 4 M MgC12 and dialyzed  immediately  against 
10 mM Tris,  pH 7.4,  containing 0.15 M  NaC1 and 0.02%  NAN3. Pooled 
fractions with the highest OD2s0 reading were stored at 40C with 100 U/mi 
kallikrein inhibitor (Calbiochem-Behring Corp.,  La Jolla,  CA) and 0.5 
mg/mi ovalbumin.  Approximately  1.5 mg of purified immunoglobulin was 
recovered  from 4 ml of serum. 
Transfection of COS-1 Cells, 
Radiolabeling and Immunoprecipitation 
COS-1 cells (4 x  105)  plated in 35-ram dishes the previous day were trans- 
fected with 10 pg supercoiled  DNA using DEAE-dextran followed by chio- 
roquine treatment as previously described (Adams  and Rose,  1985). Ap- 
proximately  44 h after transfe~tion,  cells were labeled at 3-/*C with 50 pCi 
[35S]cysteine (>1,300 Ci/mmol; Amersham Corp., Arlington Heights,  IL) 
in 0.5 ml cysteine-free Dulbecco-Vogt's modified Eagle's medium containing 
4% dialyzed  FCS for  1 h or for the time indicated.  For treatment with 
tunlcamycin, transfected  cells were pretreated with 3  pg/ml tunlcamycin 
(Sigma Chemical Co., St. Louis, MO) for 2 h, and then labeled in the pres- 
ence of the same concentration of the drug.  COS-1 or HeLa cells infected 
with recombinant vaecinia viruses were labeled 5 h after infection with 
[~sS]cysteine as described above. After labeling, cells were lysed at 0~  in 
0.5 ml of a solution containing 50 mM Tris, pH 8.0, 1% NP-40, 0.4% deoxy- 
cholate,  62.5 mM EDTA, and 100 U/ml kallikrein inhibitor per mi. Nuclei 
were removed by centrifugation at 15,000  g for 1 rain, and lysates were ad- 
justed to a final concentration of 0.3 % SDS. For immunopreeipitation  of El 
proteins, 5 Ixl of anti-peptide serum (not affinity purified) was incubated for 
2 h with 0.5 ml lysate at 4~  Antigen-antibody complexes  were isolated 
with protein A-bearing Staphylococcus aureus  (Pansorbin; Calbiochem- 
Behring Corp.), and washed four times with RIPA buffer (10 mM Tris, pH 
7.4, 0.15 M NaC1, 1% NP-40,  1% dcoxyeholate,  and 0.1% SDS).  Pellets 
were eluted by incubation in Laemmli sample buffer containing 2 % 2-mer- 
captoethanol at room temperature for 20 rain (unless otherwise noted), and 
the S. aureus was removed by centrifugation.  In the experiment shown in 
Fig. 2 B, pellets were eluted in 1 M Tris, pH 8.8, 2 % SDS, and 2 % 2-mer- 
captoethanol at 100*C for 1 rain. After removal of the S. aureus cells, super- 
natants were incubated with a final concentration of 0.33 M iodoacetamide 
for 60 min at room temperature,  and proteins were precipitated  with 9 voi 
of acetone at -20"C for 2 h. After washing in acetone,  precipitates  were 
dried and resuspended in sample buffer  without 2-mereaptoethanol.  Im- 
munoprecipitates  were  subjected  to electrophoresis in  10 or  15%  poly- 
acrylamide gels containing SDS (Laemmli,  1970). Marker proteins were 
[aC]methylated standard  molecular weight  markers (Amersham Corp.). 
Labeled proteins were detected by fluorography (Bonner and Laskey, 1974). 
Indirect Immunofluorescence Microscopy 
COS-1 cells grown on coverslips were fixed with paraformaldehyde  and per- 
meabilized with NP-40 as described (Rose and Bergmann, 1982). E1 pro- 
teins were detected by incubation with the affinity-purified anti-E1 peptide 
antibody described above (1:30) followed by affinity-purified  fluorescein- 
conjugated goat anti-rabbit IgG (1:50; Southern Bioteehnology  Associates, 
Inc., Birmingham, AL). For localization of the Golgi complex, coverslips 
were incubated with rhodamine-eonjugated  wheat germ agglutinin (1:100, 
E-Y Laboratories,  Inc., San Marco, CA). Calls were visualized with a Nikon 
Optiphot microscope equipped with fluorescence  epiillumination and a 
Nikon 40x  oil immersion plan apoehromat objective. 
Treatment of  Intact Cells with Proteases 
Transfected  COS-1 cells  were  radiolabeled  as  described  above  with 
[35S]eysteine for 90 min, and incubated in the presence of excess unlabeled 
eysteine for 90 min. Cells were then incubated for 15 min at 37"C in 0.5 
ml of PBS containing 1 mg/ml bromelain (Calbiochem-Behring  Corp.) and 
0.1  mM 2-mercaptoethanol. Parallel  dishes of transfected cells were in- 
cubated for the same period of time in the absence of bromelain, then lysed 
as  usual.  Bromelain-treated  cells were  collected  by centrifugation and 
washed three times in Tris-buffered saline, lysed, and E1 proteins were im- 
munoprecipitated  as described above.  HeLa ceils infected  with VVEI or 
VVAml,2 were labeled 5 h postinfeetion with [35S]eysteine for 60 rain. As 
described above, cells were either (a) mock digested for 15 min at 37"C, 
(b) treated with 1 mg/ml bromelain, (c) treated with I mg/ml trypsin-TICK 
(Worthington Biochemical  Corp., Freehold, NJ) in PBS, or (d) treated in 
medium with  1%  FCS containing 1 mg/ml pronase (from Streptomyces 
griseus; Boehringer Mannheim Biochemicals), which had been previously 
self digested  for 15 rain at 37~ 
Results 
Construction of  an Expression Vector  Encoding IBV  El 
A eDNA clone prepared from viral genomic RNA encoding 
the IBV E1 protein was obtained from D. Stem (Stern, 1983), 
and subjected to DNA sequence analysis. This nucleotide se- 
quence predicts a  polypeptide of 225 amino acids,  and is 
identical to that for the IBV E1 protein as reported by Bours- 
nell et al. (1984), with the exception of two nucleotides (Fig. 
1; see Materials and Methods). This sequence includes two 
potential sites for N-linked glycosylation at Asn 3 and Asn 
6, both of which are glycosylated in the E1 protein isolated 
from IBV, since the protein contains two N-linked oligosac- 
charides (Stem and Sefton, 1982b). In contrast, the MHV E1 
protein contains only O-linked carbohydrate (Neimann and 
Klenk,  1981). The three potential membrane-spanning  do- 
mains oflBV E1 include amino acids Tyr 21 through Thr 42, 
20  30  40  50 
110  120  130  140  150 
~LFKRCRS~BVSFNPESNAVGSILLTNGqqCNFAI  ESVPMVLSPIIKNGV 
"~60  ~70  ~80  190  200 
LYC  EGI;[WLAKCEPDHLPKDIFVCTPDRRNIYRMVO,  KYTGDO,  SGNKKRFAT 
210  220 
FVYAK  QSVDTOELESVATGC,  SSLYT 
Figure  1.  Predicted amino acid sequence of IBV El.  Membrane- 
spanning domains are shaded, and glycosylated asparagine residues 
are underlined. The nucleotide sequence previously published for 
this protein (Boursnell et al., 1984) differs at two nucleotides, which 
results in changing the codon for serine 2  and for isoleueine 71 to 
that for proline and threonine, respectively. 
Machamer and Rose Golgi Retention Signal  1207 Figure 2. Detection of E1 in infected and transfected COS-1 cells. 
(A) COS-I cells were either mock-infected or infected with IBV and 
radiolabeled  48 h  later with  [35S]cysteine for 2  h.  IBV proteins 
were immunoprecipitated with a rabbit anti-IBV serum (ttlBV) or 
with a rabbit anti-peptide serum specific for the carboxy terminus 
of IBV E1 (r  Positions of the IBV proteins N and E1 are 
noted,  and the anx~ marks the position of a polypeptide  that is 
most likely the spike glycoprotein, E2. (B) COS-1 cells were trans- 
fected with vector alone (pJCll9) or with pSV/IBVE1, and labeled 
44 h later with  [35S]eysteine for 2 h.  E1 was immunoprecipitated 
with  r  (C) COS-1 cells were infected with a recombinant 
vaccinia virus encoding  IBV E1  (VVE1) or as a control,  with a 
recombinant vaecinia virus encoding VSV G protein (VVG). Cells 
were labeled 5 h after infection with [35S]cysteine for 1 h, and E1 
was immunopreeipitated  with r  Samples in A and C were 
eluted in sample buffer at room temperature for 20 min, and those 
in B were eluted at 100~  followed by alkylation with iodoaceta- 
mide (see Materials and Methods).  Samples in A and B were sub- 
jected to electrophoresis in the same 15% polyacrylamide gel, and 
samples in C were subjected to electrophoresis in a 10% polyacryl- 
amide gel. 
Met 52 through Tyr 72, and Gly 78 through Ile 101 (Fig.  1). 
A  fragment containing  the  complete coding  sequence  for 
IBV E1 was subcloned into the SV40-based expression vec- 
tor,  pJCU9  (Sprague et al.,  1983).  When transfected onto 
COS cells, which provide T antigen and thus support exten- 
sive replication of the vector (Gluzman, 1981), high levels of 
protein can be expressed transiently from the late SV40 pro- 
moter. Initial attempts to detect the IBV E1  polypeptide in 
COS-1  cells  transfected  with  this  construct  (pSV/IBVE1) 
were unsuccessful. These experiments were performed with 
a rabbit hyperimmune serum raised to purified virus, which 
immunoprecipitates IBV E1 from infected chick embryo kid- 
ney cells (Stern and Sefton,  1982a).  Although E1 could not 
be detected in transfected COS-1 cells, El-specific RNA was 
readily detected in dot blots (data not shown). Inability to de- 
tect the protein could have been the result of its instability 
or  toxicity to  cells,  aberrant  splicing  from cryptic  splice 
sites, and/or a low titer of antibodies to E1 in the anti-IBV 
serum. Results obtained with hybrid proteins between IBV 
E1 and VSV G protein suggested that at least one of the prob- 
lems  was  an  insufficient  titer  of antibodies  to  E1  in  the 
anti-IBV serum (not shown). 
Detection of  lBV  E1 in Transfected Cells 
using an Anti-Peptide Antiserum 
We prepared a rabbit antiserum specific for a synthetic pep- 
tide corresponding to the carboxy-terminal 22 amino acids 
of IBV El.  A  peptide corresponding to this  region of the 
polypeptide was chosen because it is likely to be the most 
accessible in the native protein.  COS-1  cells infected with 
IBV were labeled 48  h  after infection  with  [35S]cysteine, 
and  the  cell  lysate was  subjected  to  immunoprecipitation 
with the anti-E1 peptide serum. A single polypeptide of,,o32 
kD was specifically immunoprecipitated by the anti-E1 pep- 
tide serum from IBV-infected cells (Fig. 2 A). In contrast, the 
anti-IBV serum precipitated the nucleocapsid protein (N) as 
well as E1 and trace amounts of the spike glycoprotein, E2. 
The anti-peptide serum was therefore highly specific for IBV 
El. COS-1 cells transfected with DNA encoding IBV E1 were 
labeled 44  h  after transfection with  [35S]cysteine  and sub- 
jeered to immunoprecipitation. A polypeptide co-migrating 
with  E1  from infected cells was precipitated  from COS-1 
cells transfected with pSV/IBVE1  but  not  with the vector 
pJCll9 lacking the insert encoding E1  (Fig.  2 B).  A  small 
amount of a 61-kD protein can also be observed in the im- 
munoprecipitates from transfected cells (Fig.  2 B;  see also 
Fig. 7 A). This band was specific for El-expressing COS-1 
cells, but was not consistently observed. It is probable that 
it represents a dimer of El, as the MHV E1 protein has been 
shown  to  be  susceptible  to  aggregation,  especially  when 
heated in the presence of SDS and reducing agent (Sturman, 
1977). 
In addition to the transient expression of IBV E1 in COS-1 
cells using the SV40-based vector, expression of E1 was also 
achieved in cells infected with a recombinant vaccinia virus 
that encodes the protein. This expression system is advanta- 
geous since every cell is infected and is thus expressing the 
protein of interest,  and  since replication  in  the cytoplasm 
eliminates the potential problem of aberrant splicing at cryp- 
tic splice sites (see Discussion).  Recombinant vaccinia vi- 
rus encoding IBV E1 under control of an early vaccinia pro- 
moter was constructed as described (Mackett et al.,  1984; 
Chakrabarti  et  al.,  1985).  COS-1  cells  infected  with  this 
recombinant virus (VVE1), or one encoding the VSV G pro- 
tein (VVG), were labeled 5  h  after infection with [35S]cys- 
teine,  and  lysates  were  subjected  to  immunoprecipitation 
with the anti-E1  peptide serum.  A  polypeptide which co- 
migrates with IBV E1 was readily detected in immunoprecip- 
itates from cells infected with the recombinant virus VVE1, 
but not from control cells infected with VVG (Fig.  2  C). 
Localization  of  E1 in Transfected Cells 
by Indirect Immunofluorescence 
Localization of the IBV E1 protein in transfected COS-1 cells 
was compared to  that  in  IBV-infected cells using  indirect 
immunofluorescence microscopy. Cells grown on coverslips 
were either infected with IBV or Wansfect~ with pSV/IBVE1. 
Cells were fixed and permeabilized 29 h  after infection or 
The Journal of Cell Biology, Volume 105, 1987  1208 Figure 3.  Detection of IBV E1 in infected and transfected COS-1 cells by indirect immunofluorescence microscopy. COS-1 cells grown 
on coverslips were infected with IBV or transfected with pSV/IBVEI, and fixed and permeabilized 29 h after infection or 44 h after transfec- 
tion. E1 was detected by incubation of the coverslips with the affinity-purified  anti-E1 peptide serum followed by a fluorescein-conjugated 
goat anti-rabbit IgG. The Golgi complex of  these cells was localized by staining with rhodamine-conjugated wheat germ agglutinin (WGA). 
Each set of micrographs shows the same field photographed with the fluorescein (~tCTE/) and the rhodamine (WGA) filters. Arrows indicate 
the Golgi region. Bar, ,,o10 ~tm. 
44 h  after transfection, and E1  was detected by incubation 
with the affinity-purified anti-E1 peptide antibody followed 
by a fluorescein-conjugated second antibody. The cells were 
then stained with rhodamine-conjugated wheat germ aggluti- 
nin, a  marker for the Golgi region (Virtanen et al.,  1978). 
In both infected and transfected cells, IBV E1  is localized 
in a  perinuclear region which co-localizes with the region 
stained by wheat germ agglutinin (Fig. 3). No staining of the 
plasma membrane was observed; this  suggests that E1  ac- 
cumulates intracellularly in the absence of the other viral 
proteins, as well as in IBV-infected cells. This intracellular 
accumulation has been well documented for the E1 glycopro- 
tein from MHV in infected cells (Dubois-Dalcq et al., 1982; 
Tooze et al.,  1984;  Tooze and Tooze,  1985). 
Expression of  Mutant F~ Proteins Which Lack Two 
of  the Three Putative Membrane-spanning Domains 
Our goal was to identify a structural feature of E1 that might 
be responsible for intracellular accumulation of the protein. 
Results obtained with hybrid proteins of VSV G protein and 
IBV E1 suggested that the amino-terminal half of E1 might 
contain this information. The hybrid protein G23, with the 
extracellular and transmembrane domains of G protein and 
the cytoplasmic domain of E1 was transported efficiently to 
the  cell  surface  (Puddington  et  al.,  1986),  whereas  the 
reciprocal hybrid protein 23G (with the amino-terminal and 
hydrophobic domains of E1 and the cytoplasmic domain of 
G protein) was retained intracellularly like the wild-type E1 
protein (data not shown). Oligonucleotide-directed mutagen- 
esis was performed to delete sequences encoding either the 
second and third or the first and second transmembrane do- 
mains. This would be expected to produce proteins with only 
one membrane-spanning domain (the first or the third hydro- 
phobic region, respectively) with the same membrane orien- 
tation as wild-type El. Two questions regarding the mutant 
proteins could be asked.  First,  can the first or third mem- 
brane-spanning domain mediate insertion of the protein into 
the membrane in the absence of the other two hydrophobic 
domains? Second, what is the effect of removing these re- 
gions of the protein on the intracellular accumulation of El? 
Oligonucleotides were designed to loop out regions of the 
coding sequence to precisely delete membrane-spanning do- 
mains and the intervening sequences. The mutagenesis was 
performed in phage M13 by standard methods (Zoller and 
Smith,  1982)  as  described  previously  (Machamer  et  al., 
1985;  Adams and Rose,  1985).  A  schematic representation 
of the mutant proteins is presented in Fig. 4. The codon for 
threonine 42 is fused to that for arginine 102 in the mutant 
protein that lacks the second and third hydrophobic domains 
(Am2,3),  such that only the first hydrophobic domain re- 
mains. Likewise, the codon for glutamic acid 20 is fused to 
that for glycine 77 in the mutant protein that lacks the first 
and second hydrophobic domains (Aml,2), leaving only the 
third hydrophobic domain. 
After DNA encoding the mutant proteins was subcloned 
into the expression vector, the desired mutations were con- 
firmed by DNA sequence analysis. COS-1  cells were trans- 
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Figure 4. Schematic representation of wild-type IBV El and mutant 
proteins lacking two of  the three membrane-spanning domains. The 
model depicts the predicted membrane orientation for the wild-type 
protein as well as the two mutants generated by oligonucleotide- 
directed mutagenesis which lack either the second and third hydro- 
phobic domains (Am2,3) or the first and second hydrophobic do- 
mains (Aml,2).  The point at which the coding sequence is fused 
to create the mutant proteins is also shown. 
Figure  5. Expression of  the mutant E1 proteins in transfected COS-1 
cells. COS-I cells were tmnsfecl~ with DNA encoding the wild- 
type E1 protein, or the mutant E1 proteins Am2,3 or Aml,2. Cells 
were labeled 44 h after transfection with [35S]cysteine  for 1 h. A 
parallel  set  of transfected  cells  was  pretreated  with  3  ~tg/ml 
tunicamycin (Tin) for 2 h and then labeled in the presence of the 
same concentration of the drug. E1 proteins were immunoprecipi- 
tated with the anti-E1 peptide serum and subjected to electrophore- 
sis in a 15% polyacrylarnide gel. 
fected with these DNAs, and radiolabeled with [35S]cysteine 
44 h  later.  E1  proteins were immunoprecipitated and ana- 
lyzed on SDS-polyacrylamide gels (Fig. 5). Parallel dishes 
of transfected cells were pretreated with and labeled in the 
presence of tunicamycin to determine if the mutant proteins 
were glycosylated with N-linked ohgosaccharides. As shown 
in Fig. 5, the relative mobilities of  both of  the mutant proteins 
(•27  kD) is consistent with deletion of  52 or 56 amino acids. 
In addition, as seen by comparing the mobilities of the pro- 
teins  produced  in  tunicamycin-treated  cells,  both  are 
glycosylated with N-linked oligosaccharides, indicating that 
both are inserted in the membrane of  the endoplasmic reticu- 
lum.  The  mutant  protein  Aml,2  may  be  less  efficiently 
glycosylated than  wild-type  E1  and  Am2,3,  since  bands 
representing nonglycosylated Aml,2  and  Aml,2 with  one 
oligosaccharide are also observed. The oligosaccharides on 
wild-type E1 and both of the mutant proteins appear to re- 
main in the high-mannose form, since they remain suscepti- 
ble to cleavage with endoglycosidase H  (data not shown). 
Thus, it appears that either the first or the third hydropho- 
bic domains of IBV E1 can mediate insertion of the polypep- 
tide into the lipid bilayer in vivo. Neither of the mutant pro- 
teins could be detected in the medium harvested from labeled 
transfected cells, even after a labeling period of 8 h (data not 
shown), suggesting that either the first or third hydrophobic 
domains can also serve to anchor the protein in the mem- 
brane by spanning the lipid bilayer. 
Localization of the Mutant El Proteins 
in Transfected Cells 
The intracellular distribution.of the mutant El proteins was 
analyzed by indirect immunofluorescence  microscopy. COS- 
1 cells grown on coverslips were fixed and permeabilized 44 
h after transfection. E1 proteins were visualized by staining 
with the afffinity-purified anti-E1 peptide antibody, followed 
by a fluorescein-conjugated second antibody. The results are 
presented in Fig. 6. The mutant E1 protein with only the first 
h)xlrophobic domain (Am2,3) was localized intracellularly, 
in a pattern similar to that observed for the wildltype El pro- 
tein. Prominent perinuclear staining as well as some reticu- 
lar staining was observed for both proteins.  However, the 
other mutant protein with only the third hydrophobic domain 
(Am1,2) appeared in a pattern which resembles that found 
for the  hybrid protein  G23,  which  is  transported  to  the 
plasma  membrane (Puddington  et al.,  1986).  Staining  of 
microvilli is readily detected in cells expressing both Am1,2 
and G23 (Fig. 6). This surprising finding suggested that dele- 
tion of the first and second membrane-spanning domains of 
E1  results in removal of a  structural feature of the protein 
which is essential for its accumulation in intracellular mem- 
branes.  Since the mutant protein with only the first mem- 
brane-spanning domain (A2,3) accumulates intracellularly 
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probably resides in the first hydrophobic domain. 
Although  the  results  with  indirect  immunofluorescence 
suggested that the mutant protein Aml,2 was transported to 
the plasma membrane, we sought a more definitive experi- 
ment to prove that the amino terminus of the protein was 
exposed at the cell surface. This was not possible with im- 
munofluorescence experiments,  since our antibody recog- 
nizes a determinant found only on the cytoplasmic side of the 
membrane. This proof was obtained by assessing the sensi- 
tivity of the protein to proteolysis when intact, transfected 
cells  were  treated  with  bromelain.  The  amino-terminal, 
glycosylated domain oflBV E1 in purified virus was recently 
shown  to  be  susceptible  to  digestion  with  this  enzyme 
(Cavanagh et al.,  1986).  Transfected COS-1  cells were la- 
beled for 90 min with  [35S]cysteine, followed by a  90-min 
chase period. Cells were then treated with bromelain for 15 
min. A parallel set of dishes were incubated in the absence 
of bromelain. Cells were washed and lysed, and E1 proteins 
were immunoprecipitated and subjected to electrophoresis in 
an SDS-polyacrylamide gel. Fig. 7 A shows that both wild- 
type E1  and the mutant Am2,3 are unaffected when intact 
cells are treated with bromelain. However, a proportion of 
the mutant protein Aml,2 is digested to a  form which mi- 
grates  slightly faster (arrowhead; "~18 kD)  than the  non- 
glycosylated protein, suggesting that a portion of the amino 
terminus, including the oligosaccharides, has been removed 
from the protein. 
The level of expression of the E1 proteins in transfected 
COS-1 cells was low, and these cells were fragile and suscep- 
tible to lysis during proteolysis. Thus to confirm the result 
above, we used recombinant vaccinia virus vectors to achieve 
a higher level of expression, and to allow use of another cell 
type. A recombinant vaccinia virus encoding the mutant E1 
protein Aml,2  was  constructed,  and  HeLa cells  were in- 
fected with this virus or the recombinant vaccinia virus en- 
coding wild-type El. The localization of both of these pro- 
teins  in  infected  HeLa  cells  as  determined  by  indirect 
immunofluorescence microscopy was  identical to that ob- 
served in transfected COS-1  cells (data not shown).  Cells 
were labeled 5  h  after infection with  [35S]cysteine for 60 
min,  and  then  mock-treated,  or  treated  with  bromelain, 
pronase, or trypsin. After washing and lysing the cells, E1 
proteins  were  immunoprecipitated and  subjected  to  elec- 
trophoresis in an SDS- polyacrylamide gel. As shown in Fig. 
7 B, the amino terminus of Aml,2, but not wild-type El, is 
susceptible to digestion with bromelain. The decrease in to- 
tal amount of protein observed in bromelain-treated cells ex- 
pressing both wild-type and mutant proteins (in Fig. 7, A and 
B) was a result of loss of cells and/or, cell lysis during the 
digestion. For this reason, pronase and trypsin were also in- 
cluded in the experiment shown in Fig. 7 B. When intact cells 
expressing Aml,2 were digested with pronase, a fragment of 
similar size to that obtained with bromelain was observed. 
Trypsin does not cleave the amino terminus of Aml,2, but 
since the only cleavage site in the amino-terminal domain is 
quite close to the membrane (Lys 19), this is not unexpected. 
Thus, the mutant E1 protein with only the third hydrophobic 
domain is indeed expressed at the cell surface. In a similar 
experiment using a chase period, virtually all of Aml,2 was 
digested to the smaller form (data not shown),  suggesting 
Figure 6. Localization of mutant E1 proteins in transfected cells by 
indirect immunofluorescence microscopy. COS-1 cells grown on 
coverslips were transfected with DNA encoding wild-type El, the 
mutant E1 proteins Am2,3 or Aml,2, or the hybrid protein G23. 
Cells were fixed and permeabilized 44 h after transfection, and pro- 
teins were detected by incubation with the afffinity-purified  anti-E1 
peptide serum followed  by a fluorescein-conjugated  goat anti-rabbit 
IgG. G23-expressing cells are  included to show the pattern ob- 
served for a protein known to be transported to the plasma mem- 
brane. Bar, ,'~10 Ixm. 
that this protein is efficiently transported to the plasma mem- 
brane. 
Discussion 
We have shown here that the E1 glycoprotein of the coronavi- 
rus IBV accumulates  in the Golgi region when expressed 
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wild-type and mutant E1 pro- 
teins to digestion by exogenous 
proteases.  (A)  COS-I  cells 
transfected with DNA encod- 
ing  wild-type or the  mutant 
E1 proteins Am2,3 or Aml,2 
were radiolabeled 44 h after 
transfection with [35S]cysteine 
for 90 min, followed by incu- 
bation  in  excess  unlabeled 
cysteine  for  90  min.  Intact 
cells  were  mock-treated  or 
treated with bromelain for 15 
min, and E1 proteins were im- 
munoprecipitated and subject- 
ed to electrophoresis in a 15 % 
polyacrylamide gel. (B) HeLa 
cells  were  infected with  re- 
combinant  vaccinia viruses 
encoding wild-type E1 (VVE1) 
or the mutant protein Aml,2 
(VVAml,2).  Cells  were  la- 
beled 5 h after infection with 
[35S]cysteine for 60 min,  and 
intact cells were mock-treated 
or  treated  with  bromelain, 
pronase, or trypsin for 15 min. 
E1 proteins were immunopre- 
cipitated and subjected  to elec- 
trophoresis  in  a  15%  poly- 
acrylamide  gel.  Arrowheads 
show the position of digested 
Aml,2, which migrates slight- 
ly faster than the nonglycosyi- 
ated form of the protein. 
from cDNA in transfected cells, as it does in virus-infected 
cells. Concurrent experiments in this laboratory have shown 
that the E1 protein from another coronavirus, MHV, also ac- 
cumulates in the Golgi region when expressed in transfected 
COS cells (Rottier and Rose,  1987). This indicates that the 
information for intracellular accumulation must reside in the 
E1 protein itself, and allows its use as a model for membrane 
proteins that are retained at this point in the exocytic  pathway. 
The preparation of an antiserum specific for a  synthetic 
peptide corresponding to the carboxy terminus of IBV E1 
was instrumental to our ability to detect E1  in transfected 
COS-1 cells, since a rabbit antiserum prepared to IBV did not 
have a sufficient titer of antibodies to El. The level of expres- 
sion of IBV El obtained with the SV40-based expression vec- 
tor and COS-1 cells was lower than expected by comparison 
to the other proteins we have expressed with the same vector 
(Rose and Bergmann,  1982;  Guan and Rose,  1984).  Since 
IBV is an RNA virus which replicates in the cytoplasm of the 
cell, it is possible that aberrant splicing at cryptic splice sites 
occurs when the cDNA is introduced into the nucleus. Pre- 
liminary experiments using Northern blots suggested that a 
significant proportion of the El-specific message in trans- 
fected COS-1  cells lacks the 5' half of the coding sequence, 
including  the  initiation  codon  (our  unpublished  observa- 
tions).  We have obtained higher levels of expression of E1 
using a recombinant vaccinia virus vector which replicates 
in the cytoplasm (Mackett et al.,  1984;  Chakrabarti et al., 
1985), and thus avoids the problem of aberrant splicing. This 
expression system may therefore be the one of choice for fu- 
ture studies of IBV El. 
In this study, we have gained information on tv~ aspects 
of intracellular targeting of the E1 protein: that of insertion 
into membranes and that of intracellular accumulation. Mu- 
tant E1 proteins that lacked either the first and second or sec- 
ond and third membrane-spanning domains were generated 
by oligonucleotide-directed mutagenesis  of the coding se- 
quence. We found that the mutant protein with only the first 
hydrophobic domain  (Am2,3)  or that  with only the third 
hydrophobic domain  (Aml,2)  were both inserted into the 
membrane of the endoplasmic reticulum,  since both were 
glycosylated with  N-linked oligosaccharides.  Thus,  it ap- 
pears that either the first or the third hydrophobic domain can 
function as an internal, uncleared signal sequence. Clearly, 
the third hydrophobic domain must also function as a mem- 
brane anchor because the mutant protein with only this hy- 
drophobic domain is expressed on the plasma membrane. 
The first hydrophobic domain probably also functions as a 
membrane anchor, but further experiments using  in  vitro 
translation in the presence of microsomes followed by pro- 
teolysis would be required to prove this. There are several 
examples of proteins with a single membrane-spanning do- 
main which serves to mediate membrane insertion as well as 
to anchor the protein in the lipid bilayer (Bos et al.,  1984; 
Holland et al., 1984; Lipp and Dobberstein, 1986). Also, some 
The Journal of Cell Biology,  Volume  105, 1987  1212 proteins that  span  the membrane several times have  been 
demonstrated to have more than one internal, uncleaved sig- 
nal sequence, as shown by site-directed mutagenesis and as- 
sessment of membrane insertion in vitro (Friedlander and 
Blobel,  1985;  Mueckler and Lodish,  1986). 
The most novel information gained from the mutant  E1 
proteins concerns the intraceUular accumulation of the poly- 
peptide. Deletion of the first and second, but not the second 
and third, hydrophobic domains resulted  in efficient expres- 
sion of the protein at the cell surface. This is the first demon- 
stration that an intracellular membrane protein can be trans- 
ported  to  the  plasma  membrane  after  elimination  of  a 
particular  structural  domain.  Interestingly,  Poruchynsky et 
al.  (1985)  have  shown that a rotavirus  protein normally re- 
tained in the endoplasmic reticulum is secreted when a por- 
tion of the region presumed to be the membrane anchor is 
deleted. This hydrophobic region thus appears  to contain a 
signal capable of retaining  the rotavirus  protein in the en- 
doplasmic reticulum. 
The mechanism by which the IBV E1 protein is normally 
retained intracellularly could be envisioned in two ways: ei- 
ther (a) the lack of positive signal for transport to the plasma 
membrane or (b) the presence of a signal responsible for in- 
tracellular retention. The first explanation, lack of a positive 
signal for transport to the plasma membrane, seems unlikely. 
If this were the case, fusion of Glu 20 to Gly 77 to delete 
the first and second hydrophobic domains would have to cre- 
ate a positive signal for transport.  We therefore favor the hy- 
pothesis that IBV E1 possesses a signal for retention in the 
Golgi region. This could be an active type of signal, where 
a specific sequence is recognized by another protein or lipids 
which are specifically retained in this region of the cell. Al- 
ternatively,  the  retention could be passive,  resulting  from 
structural properties of the protein which sterically constrain 
it from moving in the exocytic pathway, perhaps by inability 
to be incorporated into transport  vesicles. The transport  of 
E1 to the plasma membrane after removal of a retention sig- 
nal would result if all membrane proteins move passively by 
bulk flow unless  specifically held back.  Alternatively,  the 
protein could possess a positive signal for transport  to the 
plasma membrane as well as a signal for intracellular reten- 
tion, the latter being stronger. Removal of the retention signal 
would then result in transport  of the protein to the plasma 
membrane.  Further  experiments  designed  to  determine  if 
signals for transport to the plasma membrane exist in other 
domains of E1 should allow us to distinguish these possibil- 
ities. 
The  intracellular  accumulation  of  E1  in  coronavirus- 
infected cells results in budding of virions from intracellular 
membranes. This offers an important  advantage to the virus 
in evasion of the host immune system. Persistent infections 
are readily established by coronaviruses both in vivo and in 
vitro  (reviewed  by  Sturman  and  Holmes,  1983).  Perhaps 
conversion of the E1 protein from a plasma membrane pro- 
tein to one that is retained  intracellularly was an important 
step in the successful evolution of the coronaviruses.  Such 
a conversion could have logically occurred by incorporation 
of a retention signal into a protein which already  possessed 
signals for transport  to the plasma membrane. 
In comparing the sequences of the E1 proteins from MHV 
and IBV, Rottier et al. (1986) observed that one of the most 
conserved regions between these proteins is found in the first 
and second hydrophobic domains.  This implies that this re- 
gion plays an important  role in the function of the polypep- 
tide. Our results suggest that this function is the retention of 
the protein in the Golgi region of the cell. The elucidation 
of the mechanism by which this occurs should provide valu- 
able clues to the complex process of intracellular  transport 
and targeting  of proteins. 
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